Access and Evidence
Going Through the Motions
Both pharma and payers say they need to talk more, but are they really listening?
More Access and Evidence Articles
Access and Evidence
Navigating the Chaos
With the access landscape shifting rapidly, pharma needs to watch its step
Access and Evidence
Seeking the Holy Grail of RWE
Universal standards for real-world evidence are closer than you might think
Access and Evidence
United: How employers are changing healthcare
The growth in employer coalitions are a sign that plan sponsors are increasingly flexing their muscles, but what do they hope to achieve?
Access and Evidence
Writing the Value Story
When writing the value story for a new medicine, starting earlier in Development will make sure it’s a page-turner
Access and Evidence
Pragmatic Trials: RWE’s Hidden Gem
Pragmatic trials continue to be overlooked in the RWE space – particularly in the US. Can we expect to see wider stateside adoption?
Access and Evidence
The Naked Truth About Outcomes-Based Pricing
Hype around outcomes-based contracts has been doing the rounds for some time now, but is pharma delivering the goods?
Access and Evidence
Japan’s Perilous New Pricing Policy
The introduction of a new drug pricing reform in Japan has pharma up in arms. Are their fears justified?
Access and Evidence
Digital Health Tools Are No Fad
Data generating devices may seem gimmicky, but they are poised to transform healthcare
Access and Evidence
Overcoming The Access Hurdle
If pharma is to keep whizzing ahead, it needs to rethink its approach to market access